WuXi Pharmatech
- WX
- NYSE
- Consumer Products
- Latest 20.935
- Currency US$
- Change 0.205
- Percent Change 0.989 %
- Volume 85,425
- Wed May 22, 2013 11:54 AM EDT NYSE data delayed 15 minutes.
The Globe and Mail
- Open 20.70
- Previous Close 20.73
- High 20.98
- Low 20.525
- Bidx2 20.90
- Askx1 20.94
- 52-week High 05/15 21.14
- 52-week Low 07/27 13.00
- Beta 0.907
- Market Cap 1,465.24M
- EPS 1.19
- P/E 17.60
- Forward P/E 14.241
- PEG 1.32
- Annual Dividend --
- Yield --
News
- /C O R R E C T I O N -- WuXi PharmaTech (Cayman) Inc./
- WuXi PharmaTech Files 2012 Annual Report on Form 20-F
- Chinese Premier Li Keqiang Visits WuXi PharmaTech's Headquarter in Shanghai
- WuXi PharmaTech Receives Letter from AAALAC Commending Animal Care at Suzhou Toxicology Facility as "Exemplary"
- WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2012 Results, Share Repurchase Program
Financials & Calendars
- Sales $499,910,000
- Earnings $86,580,000
- Return on Equity n/a
- Cash Flow --
- Cash $54,130,000
- Current Ratio 2.69
12 months ended Dec 31, 2012.
Trailing 12 month results shown above.
All data is in U.S. dollars.
- Assets $742,530,000
- Liabilities $164,310,000
- Liabilities-to-Equity Ratio 0.28
Price Ratios
- Price to Sales 2.93
- Price to Book 2.53
- Price to Cash Flow n/a
Event Calendar
| Event | Last | Next | ||
|---|---|---|---|---|
| Earnings | May 13 | $0.27 | Aug 12 | $0.34 |
| Surprises | May 13 | 11.11% | n/a | n/a |
| Dividends | n/a | n/a | n/a | n/a |
| Splits | n/a | -- | n/a | n/a |
12 months ended May 22, 2013.
A look at major corporate events and financial announcements that are coming up.
Company Information
About the Company
Shanghai-based WuXi PharmaTech is the leading China-based pharmaceutical and biotechnology R&D outsourcing company. As a research- driven and customer-focused company, WuXi PharmaTech provides pharmaceutical and biotechnology companies a broad and integrated portfolio of laboratory and research manufacturing services throughout the drug discovery and development process. WuXi PharmaTech's services are designed to assist its global partners in shortening the cycle and lowering the cost of drug discovery and development by providing cost-effective and efficient outsourcing solutions that save its customers both time and money. Its operations are grouped into two segments: laboratory services, consisting of discovery chemistry, service biology, analytical, pharmaceutical development and process development services, and manufacturing, focusing on manufacturing of advanced intermediates and active pharmaceutical ingredients for R&D use.
Officers
- Ge Li, Chairman; Chief Executive Offi
- Xiaozhong Liu Executive Vice President
- Company Type: n/a
- Company Status: n/a
- Full-time Employees: n/a
-
Incorporation:
United States,
n/a -
Top 1000 Ranking:
Profit: n/a
Revenue: n/a
Assets: n/a
Head Office
288 FUTE ZHONG ROAD WAIGAOQIASHANGHAI, F4
200131
Ideas & Discussion
Live Discussion of WX on StockTwits